Thursday, November 15, 2018

‘Lazy Eye’ May Affect How Youth See Themselves at School and Play


Amblyopia, or “lazy eye,” may affect how some children see themselves in terms of their ability to do well in school, make friends and be social, and play sports, according to a study published today in JAMA Ophthalmology.

Amblyopia is a condition in which one eye has reduced vision due to misalignment or blur, and the poor vision is not caused by a problem with the eye’s health and cannot be corrected with lenses.

Elaine E. Birch, Ph.D., of the Retinal Foundation of the Southwest in Dallas and colleagues assessed self-perception in 81 children aged 8 to 13 years. The children were divided into three groups: the amblyopia group, the nonamblyopia group, and the control group. There were 50 children in the amblyopia group. The 13 children in the nonamblyopia group had mild strabismus (eye misalignment), anisometropia (unequal focus between eyes), or both. Nearly all of the children in the first two groups wore glasses. The 18 children in the control group had no vision or eye problems, and none wore glasses.

Birch and her colleagues assessed the children’s self-perception using the Self-Perception Profile for Children, which covers five domains: scholastic, social, and athletic competence; physical appearance; and behavioral conduct. It also includes a separate measurement of children’s overall sense of their worth as a person. The researchers also evaluated reading and motor skills in the amblyopia group.

Scores for physical appearance, behavioral conduct, and global self-worth did not differ significantly among all three groups. However, compared with the control group, children in the amblyopia group had significantly lower scores for scholastic and athletic competence. The researchers found that the slower the children’s reading speeds were, the lower their scores were on self-perceived scholastic competence. They also found that the less accurate the children were at aiming and catching, the lower their scores were on self-perceived scholastic, social, and athletic competence.

“These findings suggest that lower self-perception is associated with slower reading speed and worse motor skills and may highlight the wide-ranging effects of altered visual development on children with amblyopia in their everyday lives,” the researchers wrote.

Like the children in the amblyopia group, the children in the nonamblyopia group had significantly lower scores for social and athletic competence than the children in the control group. However, unlike the amblyopia group, their scores for scholastic competence did not significantly differ from those of the control group. The researchers noted that the small size of the nonamblyopia group limited their ability to determine subtle differences between the amblyopia and nonamblyopia groups.

In their discussion, the researchers considered possible reasons for the lower scores in the amblyopia and nonamblyopia groups.

“Because the children with and without amblyopia differed from controls in their self-perception of social and athletic domains, it is possible that wearing eyeglasses contributed to their altered self-perception of social and athletic competence,” Birch and colleagues wrote. “However, for the scholastic domain, only the children with amblyopia had lower scores, which was consistent with an effect solely due to amblyopia.”

In a commentary on the study, Joseph L. Demer, M.D., Ph.D., noted that further study on the impact of vision problems on youth is needed. “Amblyopia remains the largest threat to vision among children, and it is a major cause of visual loss among patients of all ages. Birch et al. are to be commended and encouraged for their work in this vital area.”
(Image: iStock/roman023)

APA 2019 Election Update


There has been a change in the lineup of candidates running for president-elect in APA’s 2019 election. Philip Muskin, M.D., M.A., has withdrawn his candidacy. Appearing on the ballot for that race will be Jeffrey Geller, M.D., M.P.H., of Worcester, Mass., and Theresa Miskimen, M.D., of Piscataway, N.J. More information about the 2019 election, including APA’s election guidelines, can be found here.


Wednesday, November 14, 2018

Glutamate Levels May Predict Outcomes of Patients at Risk of Psychosis


Changes in hippocampal function are believed to play a role in the onset of psychosis. A study published today in JAMA Psychiatry suggests that the concentration of the neurotransmitter glutamate and several other metabolites in the hippocampus may offer clues about patients who are most likely to transition to psychosis.

The findings suggest that measuring hippocampal metabolites could help psychiatrists better predict outcomes in patients at risk of developing psychosis.

For the study, Matthijs G. Bossong, Ph.D., of the University Medical Center Utrecht in the Netherlands and colleagues used an imaging technique known as proton magnetic resonance spectroscopy (1 H-MRS) to measure baseline levels of glutamate and several other metabolites in 86 individuals at high risk for psychosis and 30 healthy controls. On the day of the scanning, the researchers used several scales to assess the participants’ functioning as well as symptoms of anxiety and depression. About 18.5 months later, the researchers met face to face with 57 of the 86 participants in the high-risk group to assess whether the patients had transitioned to psychosis; they also assessed the overall functioning in this group.

In total, 12 people in the clinical high-risk group experienced a first episode of psychosis; 19 showed “good overall functioning” (Global Assessment of Function, or GAF, scale equal to or greater than 65), whereas 38 of the 57 had “poor functional outcome” (GAF less than 65), Bossong and colleagues reported. The group of patients who transitioned to psychosis were found to have had significantly higher hippocampal glutamate levels at the start of the study than those patients who did not transition. These patients also had significantly higher levels of the metabolites myo-inositol and creatine than those who did not develop psychosis. Moreover, patients with higher levels of hippocampal glutamate at baseline were found to have lower levels of overall functioning at follow-up, the authors reported.

“The findings indicate that adverse clinical outcomes in individuals at high risk for psychosis may be associated with an increase in baseline hippocampal glutamate levels, as well as an increase in myo-inositol and creatine levels,” the authors wrote.

“Pharmacological treatments that engage glutamatergic targets have been generally unsuccessful for treatment of psychotic, negative, and cognitive symptoms of schizophrenia,” Juan R. Bustillo, M.D., of the University of Mexico and colleagues wrote in an accompanying editorial. “However, because schizophrenia is highly heritable and glutamatergic-associated genes are among the most involved, in vivo glutamate measurements may still assist the delineation of subgroups of patients with vulnerable disease stages.”

For related information, see the Psychiatric News article “Multimodal Approach May Improve Ability to Predict Transition to Psychosis.”

(Image: iStock/Hank Grebe)

Tuesday, November 13, 2018

Antipsychotics May Increase Risk of Pneumonia, Meta-Analysis Suggests


Patients who take antipsychotics may be at an increased risk of pneumonia, according to a systematic review and meta-analysis published in the Journal of Psychopharmacology.

After performing a search of several databases, Olubanke Dzahini, B.Pharm., M.Sc., of the Institute of Pharmaceutical Science at King’s College London and colleagues included 14 studies with a total of 206,899 patients in the meta-analysis. By compiling, comparing, and contrasting data from these studies, the researchers sought to assess the overall risk of pneumonia in patients who took first- or second-generation antipsychotics compared with those who did not take antipsychotics. They also examined the risk of pneumonia in patients who took one of six antipsychotics (clozapine, haloperidol, olanzapine, quetiapine, risperidone, and zotepine) compared with those who did not take these medications.

Compared with those who had not taken antipsychotics, those who took first-generation antipsychotics had a 69% increased risk of pneumonia, and those who took second-generation antipsychotics had a 93% increased risk. Those who had taken any of the antipsychotics included in the analysis had an 83% increased risk of pneumonia. However, the researchers found that antipsychotic use did not significantly affect the fatality rate from pneumonia compared with no antipsychotic use.

When the researchers analyzed the data on the six antipsychotics, they found that patients who took these medications had a significantly increased risk of pneumonia compared with those who did not take the medications.

Although antipsychotic use was associated with a higher risk of pneumonia, the researchers stopped short of claiming causality, citing a lack of data from randomized, controlled trials and a failure of observational studies to control for relevant confounders like tobacco use and weight. Yet they suggested ways that antipsychotics may contribute to risk.

“Antipsychotics could increase the risk of aspiration pneumonia through multiple mechanisms, including specific impairment of the protective swallowing and cough reflexes, sedation, hypersalivation, and changes in pharyngeal and laryngeal muscle tone,” the researchers wrote.

The researchers emphasized the importance of considering patients’ existing risk factors for pneumonia, including older age, chronic respiratory disease, cerebrovascular disease, dysphagia, obesity, and smoking. “Clinicians need to be vigilant for the occurrence of pneumonia in all patients who commence antipsychotics. The potential risk needs to be balanced out against the potential benefits of antipsychotic treatment in an individual,” they wrote.

For related information, see the Psychiatric News article “GI, Pulmonary Illnesses: Most Cited for Hospitalizing Clozapine Patients.”

(Image: iStock/PeopleImages)

Friday, November 9, 2018

APA Speaks Out Against Trump Administration’s Efforts to Undercut Women’s Preventive Care


APA joined four other medical specialty organizations on Thursday to urge the Trump administration to reverse actions taken this week that will limit women’s access to contraception.

The organizations spoke out just one day after the Trump administration issued a pair of federal rules that allow some employers to opt out of a requirement under the Affordable Care Act to provide birth control coverage for their employees. The new rules allow some employers to deny coverage on religious or moral grounds.

“By undercutting women’s access to contraception, a key preventive service, at no out-of-pocket cost in private insurance plans, the final rules conflict with our firmly held belief that no woman should lose the coverage she has today,” they said.

The other four organizations that joined with APA were the American Academy of Family Physicians, the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists, and the American College of Physicians.

“These rules create a dangerous new standard for employers to deny their employees coverage based on their own moral objections. This interferes in the personal health care decisions of our patients and inappropriately inserts a patient’s employer into the patient-physician relationship,” they cautioned. Additionally, the rules also “open the door to moral exemptions for other essential physician-recommended preventive services, such as immunizations.”

The groups also warned of the harmful effects of reducing women’s access to contraceptives on public health. “We know that when women have unintended pregnancies, they are more likely to delay prenatal care, resulting in a greater risk of complications during and following pregnancy for both the woman and her child. The final rules reject these facts and the corresponding recommendations of the medical community, jeopardizing many women’s ability to maintain a vital component of their health care,” they said.

“Our organizations, which represent more than 423,000 physicians and medical students, stand together in opposition to the administration’s final rules, the Religious Exemptions and Accommodations for Coverage of Certain Preventive Services Under the Affordable Care Act and the Moral Exemptions and Accommodations for Coverage of Certain Preventive Services Under the Affordable Care Act. … We urge the administration to immediately withdraw these rules and instead focus on policies to expand access to evidence-based health care for all Americans.”

The final rules are set to take effect in January 2019.

(Image: iStock/crankyT)

Thursday, November 8, 2018

Psychiatrists May Have Greater Obligation to Warn in States With Gun Restraining Order Laws


Psychiatrists practicing in one of the many states that have enacted gun violence restraining order laws may have a greater obligation to warn family members or law enforcement in cases of suicidal patients who own firearms, according to an article published in Psychiatric Services.

In the wake of mass shooting tragedies around the country, 13 states have enacted gun violence restraining order laws, also known as extreme risk protective orders (ERPOs). The first five states to put such laws into effect were Connecticut, followed by Indiana, California, Washington, and Oregon, with the remaining states enacting them in 2018.

These laws allow petitioners to have firearms removed from individuals at risk of harming themselves or others, and more states are considering such an approach, wrote William Frizzell, M.D., and Joseph Chien, D.O., of the Department of Psychiatry at Oregon Health and Science University.

Psychiatrists and mental health professionals should determine how such laws might apply to practices in their states. “From a medical-legal perspective, invoking an ERPO law might be seen as a prudent, and perhaps even expected, intervention for suicidal patients with firearms. It might even be viewed as an extension of Tarasoff-like duties in cases of potential gun violence against others,” Frizzell and Chien wrote.

Because most of these laws are new, research is limited, but existing evidence shows that seizing guns from troubled individuals is associated with a reduction in deaths by suicide and provides a needed “cooling-off period,” Frizzell and Chien wrote. The authors called for more research to clarify the effects of these laws to inform legislators in other states about the potential benefits to public health.

Although the laws vary somewhat by state, all allow law enforcement officials—or in some cases family members—to initiate gun removal from individuals who pose a risk to themselves or others and require a low burden of proof. While most of the laws specifically exclude mental health professionals as potential petitioners, Maryland’s law does permit psychiatrists, licensed psychologists, and certain others to initiate gun removal. Some states make the presence of mental illness a central factor, whereas other states disallow its consideration by courts. Other factors, such as criminal history, history of domestic violence, and history of drug or alcohol abuse may be considered by the courts.

The authors pointed out that psychiatrists and mental health clinicians routinely interface with individuals who make statements about using a firearm to inflict injury, and such professionals should consider their duty to warn and protect in these cases. “In other words, now that there exists a legal mechanism for the removal of firearms … mental health providers implicitly could be obligated to recommend an ERPO or at least inform family or law enforcement if they believe an ERPO petition might be warranted,” Frizzell and Chien wrote.

The authors noted that psychiatrists must weigh the patient’s level of risk for gun violence against other considerations, such as patient confidentiality and Second Amendment rights. “In some cases, advising others about initiating an ERPO may be the clinically correct decision—and could save lives,” they concluded.

For related information, see the Psychiatric News article “Resource Document Offers Clinicians Guidance On Risk-Based Gun Removal Laws.”

(Image: iStock/noipornpan)

Wednesday, November 7, 2018

Number of College Students Seeking MH Care Nearly Doubles Over Decade


Over the past decade, the percentage of students at U.S. college campuses seeking mental health care has increased significantly—from 19% in 2007 to 34% in 2017, according to a study published Monday in Psychiatric Services. The most common location for the college students to receive these services was on campus, the study found.

“This study provides the most comprehensive evidence to date regarding upward trends in mental health service utilization on U.S. campuses over the past 10 years,” wrote Sarah Ketchen Lipson, Ph.D., Ed.M., of Boston University School of Public Health and colleagues. “To better meet the mental health care demand from students and reduce strain on existing services, campuses may wish not only to expand capacity but also to increase the use of preventive and digital mental health services, such as those delivered via mobile apps.”

For the study, Lipson and colleagues analyzed 10 years of data collected for the Healthy Minds Study—an annual web-based survey examining mental health, use of mental health services, and related issues among undergraduate and graduate students. Students at participating institutions were randomly recruited to participate in the survey by email and were required to be at least 18 to participate.

Of the 155,026 students (56.5% female; 74.0% white) from 196 campuses included in the sample, 26.9% screened positive for depression, and 8.2% reported suicidal ideation within the past year. Students most commonly reported receiving services for mental health care on campus, with rates increasing from 6.6% in 2007 to 11.8% in the 2016-2017 academic year. The rate of students reporting past-year treatment increased from 18.7% in 2007 to 33.8% in 2016-2017, with similar patterns for both therapy/counseling and medication use. The proportion of students with a diagnosed mental health condition also increased over this period, from 21.9% in 2007 to 35.5% in 2016-2017.

Between 2007 and 2017, students reported less stigma regarding mental illness: the percentage of students who agreed with such statements as “most people think less of a person who has received mental health treatment” (perceived stigma) or “I would think less of a person who has received mental health treatment” (personal stigma) dropped from 64.2% to 46.0% and from 11.4% to 5.7%, respectively.

“The trends revealed in this study have strained counseling centers across the country, given that many are underresourced and operate at full capacity with waitlists for much of the year,” the researchers wrote. “There are a multitude of approaches to consider for alleviating this strain, including universal prevention programs and rapid referral to community treatment.”

For more on what colleges can do to help students seeking mental health care, see the Psychiatric News article “Duck Syndrome, Social Media, and Struggling Together” by Matthew C. Fadus, M.D.

(Image: iStock/seb_ra)

Tuesday, November 6, 2018

Negative Thoughts, Fears Linked to Risk of Suicide in Patients With Psychosis


Negative thoughts about psychotic experiences and fears of losing mental control may heighten the risk of suicide in patients with psychosis who were not taking antipsychotics, suggests a report in Schizophrenia Bulletin.

“Overall, our findings emphasize the importance of clinicians promoting a recovery-focused and appropriately optimistic outlook when working with people with psychosis, taking care to avoid providing information that might heighten negative illness appraisals and/or fears of losing mental control,” wrote Paul Hutton, Ph.D., of the Edinburgh Napier University in the United Kingdom and colleagues.

Hutton and colleagues analyzed data on 68 patients in a pilot trial designed to assess the effects of cognitive therapy on individuals with schizophrenia who had not taken antipsychotics for at least six months. At the start of the study and follow-ups at nine and 18 months, the researchers measured the patients’ psychotic symptoms using the Positive and Negative Symptom Scale; they also measured negative beliefs and attitudes using the Personal Beliefs About Experiences Questionnaire and the Metacognitions Questionnaire-30.

The researchers found that symptoms of psychosis were more likely to be linked to suicidal thinking at nine to 18 months when the patients held negative thoughts and fears. Negative thoughts and fears about consequences of symptoms leading to loss of mental control accounted for 37 percent of the association between those symptoms and suicidal thinking, according to the report.

According to the researchers, the findings call for randomized, control trials of special therapies that address negative cognitive beliefs, such as metacognitive therapy, metacognitive reflection and insight therapy, and cognitive analytic therapy to examine their effect on suicidal thinking.

“Consistent with previous findings that fears of mental disintegration are strongly associated with suicide in psychosis, our results suggest that the way people appraise their symptoms and their consequences, including whether they [have] heighten[ed] concerns about losing mental control, may partly determine whether [their symptoms] lead to thoughts of suicide,” Hutton and colleagues wrote.

For related information, see the Psychiatric News article “Upping Our Game Against Suicide” by APA Past President Anita Everett, M.D.

(Image: iStock/Wavebreakmedia)

Monday, November 5, 2018

Gene Risk Scores May Predict Antipsychotic Response in Patients With First-Episode Psychosis


A study published today in AJP in Advance suggests that calculating the polygenic risk score (PRS) of a patient with first-episode psychosis can offer clues as to whether he or she will respond to antipsychotics. A PRS involves adding up the total number of genetic variants associated with schizophrenia risk in an individual’s DNA.

“Polygenic risk scores represent the combined effects of many thousands of genetic variants across the entire genome, and better represent the very complex genetic nature of schizophrenia,” said lead study author Jian-Ping Zhang, M.D., Ph.D., an assistant professor at the Feinstein Institute for Medical Research, in a press release.

Zhang and colleagues first analyzed DNA samples from 510 patients with first-episode psychosis who were participating in one of four clinical trials testing antipsychotic medications (two trials in the United States and two in Europe). The researchers identified how many genetic variants associated with the risk of developing schizophrenia each participant had. The total number of variants was used to calculate a polygenic risk score. They next compared the patients’ PRS score with how well they responded to the assigned antipsychotic (which in these four studies included amisulpride, aripiprazole, haloperidol, olanzapine, quetiapine, risperidone, and ziprasidone). The patients were considered to have responded to treatment if they experienced a reduction of 50% or more in total symptom scores from baseline to the 12-week follow-up.

The researchers found that the higher the PRS score a patient had, the more likely he/she would not respond to antipsychotic medication. When the researchers grouped the patients from all of the trials according to high and low PRS scores, they found 60.9% of patients in the low PRS group responded to antipsychotics compared with 52.1% in the high PRS group. The difference was even greater when only the two clinical trials involving people of European ancestry were analyzed; combining these two cohorts, the response rate in the low PRS group was 61.8% compared with 45.8% in the high PRS group.

“The results we found open the door for ‘precision medicine’ approaches to psychiatry, and more specifically, the use of polygene scores as a new technology for the treatment of psychiatric disorders,” said study co-author Todd Lencz, Ph.D., also of the Feinstein Institute, in the press release.

For related information, see the Psychiatric News article “Genetic Variant May Foretell Cognitive Response to Antipsychotics.”

(Image: the Biochemist Artist/Shutterstock)

Friday, November 2, 2018

Meta-Analysis Finds Group CBT Optimal Psychotherapy for Children, Adolescents With Anxiety


Group therapy may work best for children and adolescents with anxiety, a meta-analysis of various psychotherapies found, with group cognitive-behavioral therapy (CBT) showing the greatest effectiveness in reducing anxiety symptoms. The report was published this week in JAMA Psychiatry.

“The results of our analysis suggest that psychotherapy delivered in a group format may generally result in better outcomes than when delivered individually,” wrote Xinyu Zhou, Ph.D., of Chongqing Medical University in China and colleagues. The benefit “may be attributed to the additional exposure of social stimuli and interaction in the group format and thus increasing the efficacy of psychotherapy.”

Zhou and colleagues searched various databases for studies that compared any structured psychotherapy with another (or a control condition) for the acute treatment of anxiety disorders in children and adolescents (18 years or younger). The meta-analysis included 6,625 participants who received one of 11 distinct psychotherapies.

Most (93) of the 101 trials included in the meta-analysis assessed various forms of CBT (individual and/or group CBT, CBT with parental involvement, parent-only CBT, and self-help forms of CBT). Eight studies assessed forms of behavioral therapy (BT), including individual and/or group BT or individual BT with parental involvement.

The authors examined the efficacy of the various psychotherapies, as measured by the change in anxiety symptoms from baseline to the end of therapy and from baseline to the end of follow-up (≤12 months). The authors also examined post-therapy changes in quality of life and functional improvement and the acceptability of the therapies, defined as the proportion of patients who discontinued for any reason during the acute phase of treatment.

The meta-analysis revealed that most psychotherapies were significantly more effective than the wait-list condition posttreatment and at follow-up. However, only group CBT was found to be significantly more effective than other psychotherapies posttreatment and at short-term follow-up. In terms of quality of life and functional improvement, CBT delivered in various ways was significantly beneficial, compared with psychological placebo and the wait-list condition.

The authors found that self-help CBT, such as internet-assisted CBT and bibliotherapy CBT, could be useful clinical tools, since they were more effective at reducing anxiety symptoms than wait-list conditions. However, participants receiving bibliotherapy were 2.5 times to more than 9 times more likely to discontinue treatment, compared with other psychotherapies and control conditions.

“This network meta-analysis suggests that group CBT might be considered as the initial choice of psychotherapy for anxiety disorders in children and adolescents; however, more research is needed to confirm such conclusions,” the researchers wrote.

For related information, see the Psychiatric News article “Childhood Anxiety Can Be Treated—the Challenge is to Recognize It.”

(Image: iStock/asiseeit)

Thursday, November 1, 2018

APA Honors Psychiatrists Who Served in Vietnam


APA today honored psychiatrists who served in the Vietnam War with a special ceremony at the Vietnam Veterans Memorial Wall on the grounds of the National Mall in Washington, D.C.

A wreath was laid at the foot of the memorial wall for U.S. Army Capt. Peter Livingston, M.D., the only known psychiatrist to die in the war. The wreath was placed beneath the section of the wall where Livingston’s name is etched on the marble wall. Laying the wreath were Livingston’s widow, Cynthia; APA CEO and Medical Director Saul Levin, M.D., M.P.A.; APA President Altha Stewart, M.D.; and APA Assembly Speaker Bob Batterson, M.D. Mrs. Livingston attended the event along with some 150 other guests, including 17 veterans of the war and family members, as well as retired and active duty service members.

“We are here to honor men and women who made great sacrifices in service to their country in wartime,” said Stewart at the ceremony. “[I]t is an honor to stand before you to say thank you for your service then, and to the active service members, thank you for your service today.”

Stewart, who has made diversity and inclusion a prominent theme of her presidency, reminded attendees that racial strife among troops in the war, and among Americans at home, was a feature of the time. “Certainly, we have made some progress over these years, but there are many things we still have to accomplish in order for us to have the kind of open, free society that all of us aspire to.”

Batterson, who was a captain in the U.S. Army Reserve Medical Corps, said the nature of combat in Vietnam was unlike any the U.S. military had encountered in prior conflicts. He noted that psychiatrists treated traumatic stress reactions in soldiers through a combination of traditional approaches augmented with first-generation psychotropic medications. “The nature of the conflict necessitated a great deal of improvisation with these medications under war-time conditions,” he said.

Speaking directly to Cynthia Livingston, Levin said, “To give one’s life in pursuit of the ideals of freedom and equality is a noble thing but dying for a worthy cause is small consolation to those at home who must live with the profound grief and personal loss that come with the death of a loved one.

“Each name on the memorial wall [represents] someone who sacrificed life so that the ones they left behind could live in a free society,” Levin continued. “We owe it to them to live our lives to the fullest potential and never stop our pursuit of freedom and equality for all people.”

The ceremony was the result of an action paper in the Assembly written by Adam Kaul, M.D., representative from the Psychiatric Society of Virginia, and Norman Camp, M.D., an APA member and retired U.S. Army colonel who served in Vietnam.

(Image: David Hathcox)

APA Announces Candidate Changes for President-Elect in 2019 Election


There has been a change in the lineup of candidates running for president-elect in APA’s 2019 election. Philip Muskin, M.D., M.A., APA’s current secretary, has withdrawn his candidacy. Appearing on the ballot for that race will be Jeffrey Geller, M.D., M.P.H., of Worcester, Mass., and Theresa Miskimen, M.D., of Piscataway, N.J.

Geller is a professor at UMASS Medical School and medical director of a 290-bed public psychiatric hospital. He has served in the Assembly and on components for 26 years and on the Board of Trustees for 11 years. He has been an on-site consultant to 26 states. He’s received the Human Rights Award and Profiles in Courage Award from APA. He sees inpatients and outpatients daily.


Miskimen, a professor at Robert Wood Johnson medical school, is vice president at Rutgers UBHC, one of the largest providers of mental health and addiction services in the country. An APA member for nearly three decades, she has served the organization, Assembly, and Board of Trustees in many positions including DB president and speaker of the Assembly and received various recognitions including the Women’s Advocate Award.

In comments to Psychiatric News, Muskin said that the reason for his withdrawal is that he came to realize, as APA’s secretary, that serving the Association as an elected officer is a major time and service commitment. After experiencing the loss of a beloved sister and the birth of his first grandchild, he said that his most important priority at this time is his family.

Here is the slate of candidates for APA’s 2019 election. The slate is considered public but not official until it is approved by the APA Board of Trustees at its December meeting.

President-Elect
Jeffrey Geller, M.D., M.P.H.
Theresa Miskimen, M.D.

Secretary
Jeffrey Akaka, M.D.
Sandra DeJong, M.D., M.Sc.
Ramaswamy Viswanathan, M.D., D.M.Sc.

Minority/Underrepresented (M/UR) Trustee
Rahn Bailey, M.D.
Robert Cabaj, M.D.

Area 3 Trustee
Kenneth Certa, M.D.
Barry Herman, M.D., M.M.M.
Roger Peele, M.D.

Area 6 Trustee
Barbara Weissman, M.D.
Melinda Young, M.D.

Resident-Fellow Member Trustee-Elect
Lisa Harding, M.D.
Daniel Hart, M.D.
Michael Mensah, M.D., M.P.H.

The deadline for candidates who wish to run by petition is November 15. All candidates and their supporters are encouraged to review APA's Election Guidelines. For more election information, please visit the Election section on APA's website or email election@psych.org.

APA members may cast their ballots from January 2 to January 31, 2019.

Wednesday, October 31, 2018

Specialized Psychotherapy Found to Reduce Severity of Delusions in Patients With Schizophrenia


Participating in a brief course of individualized metacognitive training—a psychotherapy designed to specifically target delusional beliefs—can reduce the severity of delusions and positive symptoms in patients with schizophrenia, according to a study published Tuesday in Schizophrenia Bulletin.

The study found that patients who received metacognitive training had significant reductions in delusional thinking compared with patients who received cognitive remediation, a program designed to improve cognitive abilities. These improvements were maintained at six months.

The findings “suggest that even brief psychotherapy can help to ameliorate the symptoms of psychosis,” Ryan P. Balzan, Ph.D., of Findlers University in Adelaide, Australia, and colleagues wrote.

Patients aged 18 to 65 with a schizophrenia spectrum diagnosis and delusional beliefs were recruited for the study. Of the 54 patients included in the trial, 52 were taking antipsychotic medications; these patients continued to receive their medication throughout the study.

The patients were randomly assigned to metacognitive training or cognitive remediation. Patients in the metacognitive training group completed four two-hour sessions with a therapist over one month, where they learned techniques for increasing awareness of their own cognitive biases that may contribute to the formation and maintenance of their delusional beliefs (for example, overconfidence and belief inflexibility). Patients in the cognitive remediation group completed four therapist-led, 90-minute to two-hour sessions over the same timeframe, during which they focused on improving working and verbal memory, processing speed, problem-solving, and attention—cognitive domains commonly impaired in patients with schizophrenia.

The researchers assessed the patients’ delusions, positive symptoms, performance in several cognitive domains, and clinical insight (awareness of and attitudes toward mental illness) at the start of the trial, following the completion of the four therapy sessions, and six months later. Two patients did not complete the six-month assessment.

Patients in the metacognitive training group showed significant reductions in delusional and overall positive symptom severity and improved clinical insight relative to patients in the cognitive remediation group. In contrast, compared with those in the metacognitive training group, patients in the cognitive remediation group showed moderate improvement in problem-solving ability but in no other cognitive domains. The authors wrote that this suggests “more CR [cognitive remediation] might be required to be effective in these domains.”

In conclusion, the authors wrote, “While larger multisite trials investigating MCT+ [metacognitive training] are warranted, the present study adds to the growing literature that psychological interventions can be effective in people with psychosis.”

For related information, see the American Journal of Psychotherapy article “Application of Integrative Metacognitive Psychotherapy for Serious Mental Illness.”

(Image: iStock/Squaredpixels)

Tuesday, October 30, 2018

What Can Physicians Do to Prevent Firearm Violence?


Physicians should routinely ask patients about firearms in their home and whether guns are locked and safely stored, writes James S. Kahn, M.D., a professor of medicine at Stanford University, in an editorial published today in the Annals of Internal Medicine. The editorial was published alongside a position paper from the American College of Physicians on reducing firearm injuries and deaths in the United States.

“Firearm-related violent death is an extraordinary problem made even more alarming by the prevalence of guns in the households of persons with dementia and the variation in firearm injuries related to racial disparities,” Kahn writes. “Yet, many physicians have been unengaged or silent during this epidemic. Why? Perhaps we think firearm violence is outside our realm of influence.”

Yet Kahn says physicians routinely ask patients about their unsafe activities, risky exposures, and addictions. “Nicotine abatement programs, alcohol reduction plans, and HIV prevention efforts begin with questions … about a person’s behavior and are successful when physicians provide information to empower patients, motivating them to prevent disease and avoid disability or death. Guns should be no different.”

Kahn recommends the following advice to patients about creating a safe environment when guns are in the home: 

  • Remove the ammunition from the gun and lock the gun in a secure location.
  • Lock the ammunition in a separate location from the gun.
  • Store the keys in a different area from household keys and keep the keys out of reach of children.
  • Lock up gun-cleaning supplies.
  • Never leave a gun unattended after removing it from a safe storage place.

Kahn urges physicians to begin the conversation simply by asking, “Do you have guns in the home?” If a patient answers “yes,” the physician can follow up with a question such as “How or where do you typically store your guns?”

“If my patients say their guns are not secured or locked, then we can talk about how they might protect themselves and others from unintentionally finding and firing the guns,” Kahn writes. “We discuss what to teach children to do if they encounter a gun: Stop what they are doing, never touch the gun, leave the area, and tell an adult right away.” 

“It would be so easy to normalize this line of inquiry and add these questions to an electronic medical record along with questions about alcohol consumption, drug use, and sexual practices,” Kahn writes. “And it is not difficult to learn how to talk to patients about guns and how to counsel them about safety. We need to routinely ask, ‘Do you have guns in the home?’”

For related information, see the Psychiatric News article “Talking to Patients About Guns Necessary, But Examine Your Beliefs First.”

(Image: iStock/DmyTo)

Monday, October 29, 2018

Augmenting Interpersonal Therapy Early May Speed Improvement in Youth With Depression


Psychiatrists who treat adolescents with depression with interpersonal psychotherapy (IPT-A) should consider augmenting the treatment if there is no significant response to therapy within four weeks, suggests a small study published in the Journal of American Academy of Child & Adolescent Psychiatry.

“Waiting too long to decide whether to change treatment for an insufficient responder could mean prolonged experience of depressive symptoms and associated functional impairments,” wrote Meredith Gunlicks-Stoessel, Ph.D., of the University of Minnesota and colleagues. “On the other hand, augmenting treatment too soon might mean adding treatments that could increase risk of side effects or other burdens before giving the initial treatment sufficient time to work.”

For the study, Gunlicks-Stoessel and colleagues tracked 40 adolescents aged 12 to 17 with depression receiving 12 IPT-A sessions over a 16-week period. The participants were randomly assigned to receive a clinical evaluation after either four weeks or eight weeks, at which point treatment could be augmented if needed. Adolescents who showed an insufficient response to IPT-A (defined as less than a 20% reduction in depression symptom scores after four weeks or less than 40% reduction in depression symptom scores after eight weeks) were randomly assigned to four additional IPT-A sessions or daily fluoxetine (10 mg to 40 mg).

The authors found that the adolescents who received a clinical evaluation after four weeks had lower average depressive symptoms, as measured by the Children’s Depression Rating Scale-Revised, or CDRS-R, after 16 weeks compared with those who received the evaluation at eight weeks.

Additional analysis revealed that adolescents who received additional IPT-A sessions or adjunct fluoxetine beginning at week 4 saw statistically similar symptom improvements at week 16, the authors noted. Adolescents who received additional IPT-A sessions after four weeks saw greater symptom improvements compared with those who received the additional sessions after eight weeks. Adolescents who received fluoxetine experienced similar improvements regardless of when they began the augmentation.

“It may be that the timing of adding fluoxetine is not critical in the way that it appears to be for increasing the dose of IPT-A,” the authors wrote. “At week 4, the adolescent is about to initiate working on the interpersonal problem area and learning new communication and interpersonal problem-solving skills. It may be that meeting twice per week at this time is particularly good timing, as it provides more concentrated skill building and opportunities for engaging in interpersonal experiments in between sessions.”

For related information, see the Psychiatric News article “SSRIs/SNRIs Effective in Children, but Risks, Benefits Vary.”

(Image: iStock/Nikodash)

Friday, October 26, 2018

Cardioprotective Treatments After Heart Attack Increase Lifespan of Patients With Schizophrenia


The increased risk of mortality in patients with schizophrenia can be reduced with cardioprotective medication, such as antiplatelets, β-blockers, and statins, after a heart attack, suggests a study published in JAMA Psychiatry.

Previous studies have found that patients with schizophrenia die 10 to 15 years younger and have worse outcomes from coronary artery disease than those in the general population.

“Our study suggests that patients with schizophrenia who are treated with cardioprotective treatment after MI [myocardial infarction] have a lower mortality risk compared with patients who are not treated, similar to those treated in the general population,” wrote Pirathiv Kugathasan, M.D., of Aalborg University in Denmark and colleagues. “Cardioprotective medication after myocardial infarction should be carefully managed to improve prognosis.”

The researchers studied all adults aged 30 and older who were treated in Denmark public hospitals with first-time myocardial infarction (MI) during a 20-year period, involving 105,018 individuals, including 684 patients with a prior diagnosis of schizophrenia. The researchers followed patients up to 20 years and collected data on prescriptions received and defined five cardioprotective therapeutic drug groups: antiplatelets, vitamin K antagonists, β-blockers, angiotensin-converting enzyme inhibitors, and statins. The researchers noted use of monotherapy (treatment with one these medication groups), dual therapy (use of two), and triple therapy (use of three or more) as well as the time to all-cause mortality during the follow-up.

Compared with patients in the general population, patients with schizophrenia were less likely to receive prescriptions for cardioprotective medications after MI. Such patients were nearly nine times more likely to die compared with the general population treated; moreover, even those who received treatment were still nearly twice as likely to die as those treated in the general population.

The triple therapy provided the greatest benefit for patients, however, and patients with schizophrenia who received any combination of triple therapy had mortality rates similar to those observed of the general population who received the same treatment.

“Cardiovascular medications are a mainstay for ensuring health and preventing recurrent cardiovascular events after myocardial infarction,” Benjamin G. Druss, M.D., M.P.H., of Emory University wrote in an accompanying editorial. “The findings of the study by Kugathasan et al suggest that these medications can also play a critical role in reducing mortality among individuals with schizophrenia.”

For related information, see the Psychiatric News article “Patients With Serious Mental Illness Need Better Primary Care Integration, Health Advocacy.”

(Image: iStock/Eraxion)

Thursday, October 25, 2018

Children With Anxiety Disorders Face Higher Risk for Self-Harm, ER Visits, Hospitalization


Children with newly diagnosed anxiety disorders were significantly more likely to experience serious medical events requiring treatment in the emergency room (ER) or inpatient hospitalization than children who did not have these disorders, according to a study published in Depression and Anxiety.

“Within two years following a new anxiety disorder diagnosis, a significant proportion of children have a mental health–related hospitalization, inpatient treated self-harm event, or ER visit, which translates to a sizable number of children, given the prevalence of anxiety disorders,” wrote author Greta A. Bushnell, Ph.D., a postdoctoral fellow in the Department of Epidemiology at Columbia University Mailman School of Public Health, and colleagues. Some 54 million children worldwide are estimated to have an anxiety disorder, according to the Global Burden of Disease Pediatrics Collaboration.

For the study, Bushnell and colleagues identified nearly 200,000 commercially insured children (aged 3 to 17) who were newly diagnosed with anxiety disorder in an office setting and had not received treatment for anxiety. The authors then examined the incidence of mental health–related hospitalization, inpatient treatment for suicide and self-inflicted injury, suicidal ideation, and ER visits in these children over a two-year period. They also examined the incidence of these events in children without an anxiety diagnosis (matched by age, sex, geographical region).

Within two years of diagnosis with anxiety, the children were three times more likely to have had a mental health related–hospitalization than children without an anxiety diagnosis (3.2% vs. 0.9%). Nearly one-third of the children with an anxiety diagnosis were treated in the ER (31.9%) versus about one-fifth of the children without an anxiety diagnosis (21.8%). Children with anxiety were also more than three times more likely to have suicidal ideation (1.7% vs. 0.4%) or receive inpatient treatment for self-harm (0.13% vs. 0.03%).

The rate of serious events were even higher than expected by researchers, Bushnell told Psychiatric News. “For example, more than 3% of youth aged 14 to 17 years had a mental health–related hospitalization in the year following a new anxiety diagnosis. An important next step would be to examine how we can improve follow-up care and treatment to reduce these events,” she said.

“The findings can help inform discussions providers have with patients and caregivers when a child is newly diagnosed with anxiety, including discussions on monitoring anxiety symptoms and when to seek additional care to prevent serious events,” Bushnell added. “Our results draw attention to the importance of follow-up care, particularly in older children with psychiatric comorbidities.”

For related information, see the Psychiatric News article “Peer Program Helps High Schoolers Handle Depression, Anxiety.”

(Image: iStock/vitapix)

Wednesday, October 24, 2018

Support at Home, in Community May Protect Against Emotional Distress, Substance Use in Transgender Youth


Transgender and gender-diverse youth who feel close with their parents are less likely to experience emotional distress and engage in substance use compared with those reporting less connected relationships with parents, according to a study in the American Journal of Preventive Medicine. The study also found that youth who feel safe at school and have stronger relationships with teachers and other adults are less likely to experience depression, suicidality, and engage in substance use.

“Given that transgender and gender-diverse [TGD] youth report lower levels of connectedness and safety, bolstering an explicitly transgender and gender-diverse−friendly network of caring parents, safe and supportive schools, and connections to adults in the community may support efforts to eliminate disparities in depression, suicidality, and substance use,” Amy L. Glower, Ph.D., of the University of Minnesota and colleagues wrote.

For the study, Glower and colleagues examined data from the 2016 Minnesota Student Survey—a survey that asks students about school climate, bullying, out-of-school activities, health and nutrition, emotional and mental health, relationships, substance use, and more. As part of the survey, students in the ninth and 11th grades were asked, “What is your biological sex?” (response options: male/female) and whether they “identify as transgender, genderqueer, genderfluid, or unsure about their gender identity” (yes/no).

The researchers examined associations between eight protective factors (connectedness to parents, adult relatives, friends, adults in the community, and teachers; youth development opportunities; and feeling safe in the community and at school) and depression, suicidality, and substance use (alcohol, binge drinking, marijuana, nicotine) among 2,168 adolescents who identified as transgender, genderqueer, genderfluid, or questioning their gender.

Of the 2,168 included in the analysis, 57.9% met the cutoff score for additional depression screening using the Patient Health Questionnaire-2, 44.9% reported suicidal ideation, and 16.7% reported a suicide attempt; substance use ranged from 11.2% (binge drinking) to 25.9% (any nicotine use). Feeling more connected to parents was related to significantly lower odds of all indicators of emotional distress and substance use relative to those reporting less connected relationships with parents, the authors reported.

“Given that TGD youth report less connectedness with their parents than their cisgender peers, increasing investment in programs offering support and guidance to parents of TGD youth and linking parents to existing supports (e.g., through health care, schools, religious institutions) may be effective ways to bolster the development of these caring relationships,” the authors concluded.

For related information, see the Psychiatric News article “Psychiatrists Need to Prepare to Care for Gender-Variant Patients” and the Psychiatric Services article “Affirming Gender Identity of Patients With Serious Mental Illness.”

(Image: iStock/PeopleImages)

Tuesday, October 23, 2018

Haloperidol, Ziprasidone Found Ineffective in Treating Patients With Delirium in the ICU


Neither haloperidol nor ziprasidone, medications commonly used to treat psychosis, had any benefit over placebo in treating patients for delirium in the intensive care unit (ICU), according to a study published Monday in the New England Journal of Medicine.

“For more than 40 years, intravenous antipsychotic medications have been used to treat delirium in hospitalized patients,” wrote E.W. Ely, M.D., of the Vanderbilt University Medical Center and colleagues. “In this double-blind, randomized, placebo-controlled trial of intravenous antipsychotic medications for the treatment of delirium in the ICU, there was no evidence that either haloperidol or ziprasidone led to a shorter duration of delirium and coma.”

The study involved patients with acute respiratory failure or shock who developed hypoactive or hyperactive delirium at 16 U.S. medical centers. Of the 566 patients who developed delirium during the trial, 192 were randomly assigned to receive haloperidol (maximum intravenous dose, 20 mg daily), 190 received ziprasidone (maximum intravenous dose, 40 mg daily), and 184 received placebo. Patients were discontinued from drug or placebo after 14 days or at ICU discharge, whichever occurred first.

Delirium was assessed using the Confusion Assessment Method for the ICU (CAM-ICU). The primary endpoint was the number of days alive without delirium or coma during the 14-day intervention period. A secondary endpoint was duration of delirium.

The researchers found no significant difference between the treatment groups on the primary endpoint: the median number of days alive without delirium or coma was 7.9 in the haloperidol group, 8.7 in the ziprasidone group, and 8.5 in the placebo group. Neither haloperidol nor ziprasidone led to a shorter duration of delirium compared with placebo.

“Why did the trial fail to show benefit? It is likely that our concept of delirium is flawed,” suggested Thomas P. Bleck, M.D., of the Department of Neurological Science at Rush Medical College, Chicago, in an accompanying editorial.

“The neurochemistry of sudden alteration in mentation [mental activity] is complex and involves several neurotransmitters as well as structural, immunologic, and network alterations and possible brain infection that is not clinically evident,” he wrote. “The investigators deserve credit for conducting a difficult trial, but it would have been astounding if there were a single magic bullet for the restitution of normal brain function in ICU patients with delirium.”

For related information, see the Psychiatric News article “Point-of-Care EEG Device Could Ease Efforts to Detect Delirium.”

(Image: iStock/A stockphoto)

Monday, October 22, 2018

Patients With OUD Who Receive Extended-Release Naltrexone May Be More Likely to Stay in Treatment


Naltrexone is a proven treatment for opioid use disorder (OUD), but its clinical usefulness, when taken orally, has been limited by poor adherence among patients, according to several studies. A study in AJP in Advance now suggests that patients with OUD may be twice as likely to stay in therapy if they receive monthly injections of extended-release naltrexone (XR-naltrexone) following opioid withdrawal compared with daily oral naltrexone.

“These study findings have immediate clinical relevance for treatment of opioid use disorder at a time when an opioid epidemic continues unabated in the United States,” wrote Maria Sullivan, M.D., Ph.D., of Columbia University and colleagues. “Given that postdetoxification outpatient treatment without pharmacotherapy yields poor completion rates, high (60%−90%) relapse rates, and heightened risk of overdose and death, XR-naltrexone may be a viable alternative to prevent relapse in patients seeking treatment for opioid use disorder who do not prefer an agonist approach [such as methadone or buprenorphine].”

Sullivan and colleagues enrolled 60 adults aged 18 to 60 who met DSM-IV criteria for opioid dependence in the study. All participants completed an inpatient medication-assisted opioid withdrawal program and were transitioned to naltrexone therapy. Thirty-two patients were randomly assigned to treatment with oral naltrexone (50 mg/day) and 28 were assigned to treatment with XR-naltrexone (380 mg per injection every four weeks) for 24 weeks.

All participants were asked to visit the clinic three times per week for the first two weeks and then twice weekly for the remainder of the 24-week study. During each clinic visit, the patients took a urine test, discussed any recent substance use, and received a behavioral therapy session. The goal of the behavioral therapy was to educate, motivate, and support patients through the process of opioid detoxification, naltrexone induction, and successful naltrexone maintenance. Therapy goals were reinforced with a reward system whereby patients could win gift vouchers after achieving goals or milestones.

After six months, 12 of the 28 (43%) patients receiving XR-naltrexone had dropped out of treatment, compared with 23 of 32 (72%) patients in the oral naltrexone group. There were no significant differences in side effects between the two groups, other than a higher rate of insomnia among patients taking oral naltrexone. There were nine serious adverse events, but only one was found to be related to medication: one patient receiving XR-naltrexone developed allergic hives and was removed from the study.

“These results support the use of XR-naltrexone combined with behavioral therapy as an effective treatment for patients seeking opioid withdrawal and nonagonist treatment for preventing relapse to opioid use disorder,” the researchers concluded.

To read more about naltrexone, see the Psychiatric News article “Low-Dose Naltrexone May Mitigate Severity of Opioid Withdrawal During Detox.”

(Image: iStock/FilippoBacci)

Disclaimer

The content of Psychiatric News does not necessarily reflect the views of APA or the editors. Unless so stated, neither Psychiatric News nor APA guarantees, warrants, or endorses information or advertising in this newspaper. Clinical opinions are not peer reviewed and thus should be independently verified.